Back to Search
Start Over
Reducing arthritis fatigue impact: Two-year randomised controlled trial of cognitive behavioural approaches by rheumatology teams (RAFT)
- Source :
- Hewlett, S, Almeida, C, Ambler, N, Blair, P S, Choy, E, Dures, E, Hammond, A, Hollingworth, W, Kadir, B, Kirwan, J, Plummer, Z E, Rooke, C, Thorn, J, Turner, N, Pollock, J 2019, ' Reducing arthritis fatigue impact : Two-year randomised controlled trial of cognitive behavioural approaches by rheumatology teams (RAFT) ', Annals of the Rheumatic Diseases, vol. 78, no. 4, pp. 465-472 . https://doi.org/10.1136/annrheumdis-2018-214469, Annals of the Rheumatic Diseases
- Publication Year :
- 2019
- Publisher :
- BMJ Publishing Group, 2019.
-
Abstract
- ObjectivesTo see if a group course delivered by rheumatology teams using cognitive-behavioural approaches, plus usual care, reduced RA fatigue impact more than usual care alone.MethodsMulticentre, 2-year randomised controlled trial in RA adults (fatigue severity>6/10, no recent major medication changes). RAFT (Reducing Arthritis Fatigue: clinical Teams using CB approaches) comprises seven sessions, codelivered by pairs of trained rheumatology occupational therapists/nurses. Usual care was Arthritis Research UK fatigue booklet. Primary 26-week outcome fatigue impact (Bristol RA Fatigue Effect Numerical Rating Scale, BRAF-NRS 0–10). Intention-to-treat regression analysis adjusted for baseline scores and centre.Results308/333 randomised patients completed 26 week data (156/175 RAFT, 152/158 Control). Mean baseline variables were similar. At 26 weeks, the adjusted difference between arms for fatigue impact change favoured RAFT (BRAF-NRS Effect −0.59, 95% CI –1.11 to -0.06), BRAF Multidimensional Questionnaire (MDQ) Total −3.42 (95% CI –6.44 to -0.39), Living with Fatigue −1.19 (95% CI –2.17 to -0.21), Emotional Fatigue −0.91 (95% CI –1.58 to -0.23); RA Self-Efficacy (RASE, +3.05, 95% CI 0.43 to 5.66) (14 secondary outcomes unchanged). Effects persisted at 2 years: BRAF-NRS Effect −0.49 (95% CI −0.83 to -0.14), BRAF MDQ Total −2.98 (95% CI −5.39 to -0.57), Living with Fatigue −0.93 (95% CI −1.75 to -0.10), Emotional Fatigue −0.90 (95% CI −1.44, to -0.37); BRAF-NRS Coping +0.42 (95% CI 0.08 to 0.77) (relevance of fatigue impact improvement uncertain). RAFT satisfaction: 89% scored > 8/10 vs 54% controls rating usual care booklet (pConclusionMultiple RA fatigue impacts can be improved for 2 years by rheumatology teams delivering a group programme using cognitive behavioural approaches.Trial registration numberISRCTN52709998.
- Subjects :
- Male
Coping (psychology)
Emotions
Arthritis
Severity of Illness Index
law.invention
Arthritis, Rheumatoid
0302 clinical medicine
Randomized controlled trial
law
Adaptation, Psychological
Immunology and Allergy
Medicine
030212 general & internal medicine
Centre for Health and Clinical Research
Fatigue
Cognition
cognitive behavioural therapy
Middle Aged
Treatment Outcome
Patient Satisfaction
Rheumatoid arthritis
Female
BRTC
Cognitive Behavioural Therapy
Randomised Controlled Trial
Adult
medicine.medical_specialty
Immunology
Rheumatoid Arthritis
BTC (Bristol Trials Centre)
General Biochemistry, Genetics and Molecular Biology
03 medical and health sciences
Rheumatology
Rating scale
Internal medicine
Humans
rheumatoid arthritis, fatigue, cognitive behavioural therapy, randomised controlled trial
Aged
Patient Care Team
030203 arthritis & rheumatology
Cognitive Behavioral Therapy
business.industry
medicine.disease
Self Care
Social Class
Usual care
Physical therapy
fatigue
business
randomised controlled trial
Subjects
Details
- Language :
- English
- ISSN :
- 00034967 and 14682060
- Database :
- OpenAIRE
- Journal :
- Hewlett, S, Almeida, C, Ambler, N, Blair, P S, Choy, E, Dures, E, Hammond, A, Hollingworth, W, Kadir, B, Kirwan, J, Plummer, Z E, Rooke, C, Thorn, J, Turner, N, Pollock, J 2019, ' Reducing arthritis fatigue impact : Two-year randomised controlled trial of cognitive behavioural approaches by rheumatology teams (RAFT) ', Annals of the Rheumatic Diseases, vol. 78, no. 4, pp. 465-472 . https://doi.org/10.1136/annrheumdis-2018-214469, Annals of the Rheumatic Diseases
- Accession number :
- edsair.doi.dedup.....15e81e2a210d0e136f7694ea80cc27ae
- Full Text :
- https://doi.org/10.1136/annrheumdis-2018-214469